TY - JOUR
T1 - Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
AU - Petroni, Giulia
AU - Buqué, Aitziber
AU - Coussens, Lisa M.
AU - Galluzzi, Lorenzo
N1 - Funding Information:
L.M.C. acknowledges funding from the NIH (1U01 CA224012, U2C CA233280, R01 CA223150, R01 CA226909, R21 HD099367), the Knight Cancer Institute, the Brenden-Colson Center for Pancreatic Care at Oregon Health and Science University (OHSU). The L.G. lab is supported by a Breakthrough Level 2 grant from the US DoD BRCP (#BC180476P1), by the 2019 Laura Ziskin Prize in Translational Research (#ZP-6177, PI: Formenti) from Stand Up to Cancer (SU2C), by a Mantle Cell Lymphoma Research Initiative (MCL-RI, PI: Chen-Kiang) grant from the Leukaemia and Lymphoma Society (LLS), by a start-up grant from the Dept. of Radiation Oncology at Weill Cornell Medicine (New York, USA), by a Rapid Response Grant from the Functional Genomics Initiative (New York, USA), by industrial collaborations with Lytix Biopharma (Oslo, Norway) and Phosplatin (New York, USA), and by donations from Phosplatin (New York, USA), the Luke Heller TECPR2 Foundation (Boston, USA), Sotio a.s. (Prague, Czech Republic), Onxeo (Paris, France) and Noxopharm (Chatswood, Australia).
Funding Information:
L.M.C. acknowledges funding from the NIH (1U01 CA224012, U2C CA233280, R01 CA223150, R01 CA226909, R21 HD099367), the Knight Cancer Institute, the Brenden-Colson Center for Pancreatic Care at Oregon Health and Science University (OHSU). The L.G. lab is supported by a Breakthrough Level 2 grant from the US DoD BRCP (#BC180476P1), by the 2019 Laura Ziskin Prize in Translational Research (#ZP-6177, PI: Formenti) from Stand Up to Cancer (SU2C), by a Mantle Cell Lymphoma Research Initiative (MCL-RI, PI: Chen-Kiang) grant from the Leukaemia and Lymphoma Society (LLS), by a start-up grant from the Dept. of Radiation Oncology at Weill Cornell Medicine (New York, USA), by a Rapid Response Grant from the Functional Genomics Initiative (New York, USA), by industrial collaborations with Lytix Biopharma (Oslo, Norway) and Phosplatin (New York, USA), and by donations from Phosplatin (New York, USA), the Luke Heller TECPR2 Foundation (Boston, USA), Sotio a.s. (Prague, Czech Republic), Onxeo (Paris, France) and Noxopharm (Chatswood, Australia).
Publisher Copyright:
© 2022, Springer Nature Limited.
PY - 2022/6
Y1 - 2022/6
N2 - Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple tumours. However, only a few patients respond to ICIs, which has generated considerable interest in the identification of resistance mechanisms. One such mechanism reflects the ability of various oncogenic pathways, as well as stress response pathways required for the survival of transformed cells (a situation commonly referred to as ‘non-oncogene addiction’), to support tumour progression not only by providing malignant cells with survival and/or proliferation advantages, but also by establishing immunologically ‘cold’ tumour microenvironments (TMEs). Thus, both oncogene and non-oncogene addiction stand out as promising targets to robustly inflame the TME and potentially enable superior responses to ICIs.
AB - Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple tumours. However, only a few patients respond to ICIs, which has generated considerable interest in the identification of resistance mechanisms. One such mechanism reflects the ability of various oncogenic pathways, as well as stress response pathways required for the survival of transformed cells (a situation commonly referred to as ‘non-oncogene addiction’), to support tumour progression not only by providing malignant cells with survival and/or proliferation advantages, but also by establishing immunologically ‘cold’ tumour microenvironments (TMEs). Thus, both oncogene and non-oncogene addiction stand out as promising targets to robustly inflame the TME and potentially enable superior responses to ICIs.
UR - http://www.scopus.com/inward/record.url?scp=85126269608&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126269608&partnerID=8YFLogxK
U2 - 10.1038/s41573-022-00415-5
DO - 10.1038/s41573-022-00415-5
M3 - Review article
C2 - 35292771
AN - SCOPUS:85126269608
SN - 1474-1776
VL - 21
SP - 440
EP - 462
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
IS - 6
ER -